Health Condition 1: K740- Hepatic fibrosis
Conditions
Interventions
Intervention1: NA: NA
Control Intervention1: NA: NA
Sponsors
Kasturba Medical College Manipal
Eligibility
Inclusion criteria
Inclusion criteria: Metabolic dysfunction associated steatotic liver disease(MASLD) defined as presence of hepatic steatosis by imaging(USG )or biopsy with atleast one of the cardiometabolic criteria which includes BMI more than 25 kg/m2 or WC more than 94 cm in males or 80 cm in females FBS more than 100, PPBS more than 200,HBA1C more than 5.7 or known case of T2DM BP more than 130/85mmhg Plasma triglyceride more than 170 mg/dl Plasma HDL less than 40mg/dl in males HDL less than 50mg/dl in females Age less than 65 years and more than 18 years Average daily alcohol intake less than 20g/day female, less than 40gm/day in males
Exclusion criteria
Exclusion criteria: age more than 65 years and less than 18 years daily alcohol intake on more than 20g/day in female, more than 40g/day in male diagnosis of cirrhosis at histology or at clinical ground presence of hepatocellular carcinoma, ascites, portal hypertension; other comorbid liver diseases (autoimmune hepatitis, HBV, HCV, alcoholic liver disease) atrial fibrillation; left bundle branch block; history of coronary artery disease (previous myocardial infarction, previous percutaneous coronary intervention or previous coronary artery bypass graft) moderate-to-severe mitral and/or aortic valve disease; hypertrophic, infiltrative and/or dilated cardiomyopathy history of congenital heart disease left ventricular ejection fraction (LVEF)less than 50% acute coronary syndrome, acute congestive heart failure, acute respiratory failure, acute renal failure hemodynamic instability poor echocardiographic acoustic windows (not adequate for appropriate visualization and definition of endocardial border of all cardiac chambers) lack of consent
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| : Myocardial deformation imaging parameters like GLS using speckle-tracking strain echocardiography in assessing subclinical myocardial dysfunction. Liver Stiffness measurement using Fibroscan to assess liver fibrosis. Timepoint: Baseline | — |
Secondary
| Measure | Time frame |
|---|---|
| NATimepoint: NA | — |
Countries
India
Contacts
Public ContactAnmol Malhotra
Kasturba Medical College Manipal
Outcome results
None listed